HER2 Mutation-Related Tumors research hub
11 indexed studies · 5 currently recruiting
- recruitingPHASE1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This study is testing a new medicine called IAM1363 for advanced cancers with a specific change called HER2. It aims to find a safe and effective dose, including for breast, lung, and stomach cancers that have spread to the brain.
United States · France · Ireland - recruitingPHASE2, PHASE3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
This study is looking at a new medicine, RO7771950, for HER2-positive breast cancer that has spread or is hard to remove. It compares RO7771950 with an existing medicine, tucatinib, both given with trastuzumab and capecitabine. The aim is to see if the new medicine works well and is safe.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
This study looks at a new drug called tucatinib for HER2-positive breast cancer that has spread. We want to see if adding tucatinib to standard treatments (trastuzumab and pertuzumab) helps more than a dummy pill (placebo). It also checks for side effects.
United States · Australia · Austria - active not recruitingPHASE1, PHASE2
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
This study is testing a new medicine, ZN-A-1041, for people with advanced cancers that have a specific marker called HER2. It will look at how safe and effective ZN-A-1041 is, both alone and with other usual treatments, for solid tumours including breast cancer.
United States · Australia · France - active not recruitingPHASE1
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
This study looks at combining two drugs, palbociclib and avelumab, for a specific type of advanced breast cancer called triple negative. We want to find the safest dose and see how well it works, especially for cancers with a particular marker called AR.
United Kingdom - active not recruitingPHASE3
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
This study looks at a new drug, tucatinib, combined with T-DM1 to treat advanced HER2-positive breast cancer. It aims to see if this combination works better than T-DM1 alone for cancer that has spread or can't be removed by surgery.
United States · Australia · Austria - recruitingPHASE2
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
This study looks at a new drug, inavolisib, combined with standard hormone and anti-HER2 therapy for a specific type of early breast cancer. The aim is to see if adding inavolisib can improve treatment before surgery for HER2-positive, HR-positive, PIK3CA-mutant breast cancer.
Germany · Italy - recruiting
Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer
This study looks at why some women with a specific type of breast cancer (HER2-positive) get cancer spreading to their brain more than others. By understanding the risks, doctors hope to find these brain recurrences earlier and offer better, more personalised treatments.
France - active not recruitingPHASE2
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
This study looks at a new way to treat HER2-positive breast cancer that has come back locally or spread. It tests a two-step treatment: first, a medicine called T-DXd, followed by another medicine combo, PHESGO, to see how well they work.
United States · France · Germany - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - active not recruitingPHASE1
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
This study is testing a new drug, ELVN-002, with existing treatments like trastuzumab and chemotherapy. It's for adults with certain advanced HER2-positive cancers, including breast, stomach, and bowel cancer. The main goal is to find a safe dose and see how well it works.
United States · Belgium · France